Adherence to monitoring iron indices at the initiation of erythropoiesis-stimulating agents or hypoxia-inducible factor prolyl hydroxylase inhibitors
Open Access
- 16 September 2025
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (1) , 57-64
Abstract
Background: Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors have been used for the treatment of anemia in patients with chronic kidney disease not receiving dialysis since 2020. In September 2020, the Japanese Society of Nephrology published recommendations for the appropriate use of HIF-PH inhibitors, which emphasized monitoring iron indices. However, real-world adherence to these recommendations remains unclear. Methods: We retrieved the data of new users of erythropoietin-stimulating agents (ESAs) or HIF-PH inhibitors from a large Japanese claims database (DeSC, Tokyo, Japan) between 2018 and 2022. Adherence to iron testing before and after the treatments was analyzed using modified Poisson regression and Cox models. Facility-level variations were assessed via mixed-effects models. Results: We identified 105,346 patients who had a new prescription of ESAs ( n = 86,263) or HIF-PH inhibitors ( n = 19,083) and did not have kidney failure with replacement therapy. The proportion of HIF-PH inhibitor use increased from 3.6% in 2020 to 42.7% in 2022. During the study period, testing frequency for serum iron, serum TIBC or UIBC, and ferritin ranged from 57.2–59.8%, 39.2–42.8%, and 50.6–52.6%, respectively. Multivariate analysis showed that adherence to testing was significantly higher in university hospitals, Diagnosis Procedure Combination-affiliated DPC hospitals, and non-DPC hospitals compared with clinics. A similar tendency was observed in testing after the index date. Conclusions: The type of facility was the primary determinant of adherence to the recommendation for iron indices testing before the initiation of ESAs or HIF-PH inhibitors. Targeted educational interventions in low-adherence settings may help improve adherence rates and optimize patient care.Keywords
Funding Information
- Ministry of Health, Labour and Welfare (21AA2007)
- Ministry of Health, Labour and Welfare (22AA2003)
- the Ministry of Education, Culture, Sports, Science and Technology, Japan (20H03907)
- The University of Tokyo
This publication has 31 references indexed in Scilit:
- Autonomous medical evaluation for guideline adherence of large language modelsnpj Digital Medicine, 2024
- Iron-Deficiency Anemia in CKD: A Narrative Review for the Kidney Care TeamKidney Medicine, 2023
- Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney International, 2023
- Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney DiseaseKidney International Reports, 2021
- An overview of clinical decision support systems: benefits, risks, and strategies for successnpj Digital Medicine, 2020
- Comparing the Trends of Electronic Health Record Adoption Among Hospitals of the United States and JapanJournal of Medical Systems, 2019
- Intermediate and advanced topics in multilevel logistic regression analysisStatistics in Medicine, 2017
- The median hazard ratio: a useful measure of variance and general contextual effects in multilevel survival analysisStatistics in Medicine, 2016
- Factors Associated with Ordering Laboratory Monitoring of High-Risk MedicationsJournal of General Internal Medicine, 2014
- The trends in EMR and CPOE adoption in Japan under the national strategyInternational Journal of Medical Informatics, 2013